CONMED CORPORATION Finance Lease, Right-of-Use Asset, Amortization
CONMED CORPORATION (CNMD) reported Finance Lease, Right-of-Use Asset, Amortization of $365.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-02-17
- CONMED CORPORATION finance lease, right-of-use asset, amortization for the quarter ending 2019-12-31 was $76.00K.
- CONMED CORPORATION finance lease, right-of-use asset, amortization for the quarter ending 2019-09-30 was $55.00K.
- CONMED CORPORATION finance lease, right-of-use asset, amortization for the quarter ending 2019-06-30 was $54.00K.
- CONMED CORPORATION finance lease, right-of-use asset, amortization for the quarter ending 2019-03-31 was $53.00K.
- CONMED CORPORATION finance lease, right-of-use asset, amortization for fiscal 2025 was $365.00K, a 3.95% decline from fiscal 2024.
- CONMED CORPORATION finance lease, right-of-use asset, amortization for fiscal 2024 was $380.00K, a 10.47% increase from fiscal 2023.
- CONMED CORPORATION finance lease, right-of-use asset, amortization for fiscal 2023 was $344.00K, a 13.13% decline from fiscal 2022.
- CONMED CORPORATION finance lease, right-of-use asset, amortization for fiscal 2022 was $396.00K, a 1.80% increase from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2025-12-31 | $365.00K 10-K · filed 2026-02-17 | |||
| 2024-12-31 | $380.00K 10-K · filed 2026-02-17 | |||
| 2023-12-31 | $344.00K 10-K · filed 2026-02-17 | |||
| 2022-12-31 | $396.00K 10-K · filed 2025-02-18 | |||
| 2021-12-31 | $389.00K 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $355.00K 10-K · filed 2023-02-21 | |||
| 2019-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $131.00K derived: sum of 2 quarters · filed 2022-02-22 | $185.00K derived: sum of 3 quarters · filed 2022-02-22 | $238.00K 10-K · filed 2022-02-22 |
| 2019-09-30 | $55.00K 10-Q · filed 2019-10-31 | $109.00K derived: sum of 2 quarters · filed 2019-10-31 | $162.00K 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $54.00K 10-Q · filed 2019-08-01 | $107.00K 10-Q · filed 2019-08-01 | ||
| 2019-03-31 | $53.00K 10-Q · filed 2019-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |